ILTOO Pharma Announces Publication of Phase IIb Trial Results in the Lancet Demonstrating Safety and Efficacy of Low-Dose IL-2 in ALS

ILTOO Pharma Announces Publication of Phase IIb Trial Results in the Lancet Demonstrating Safety and Efficacy of Low-Dose IL-2 in ALS. ILTOO Pharma is pleased to welcome the publication in The Lancet of the results from the MIROCALS phase IIb clinical trial shows that low-dose interleukin-2, a therapy pioneered by ILTOO Pharma, significantly improves survival and slows functional decline in patients with Amyotrophic Lateral Sclerosis, a fatal neurological disease with limited therapeutic options.

The release as fetched from its publisher. iltoopharma.com ↗